Thermo Fisher mycoplasma detection tech accepted for cell therapies

By Flora Southey

- Last updated on GMT

Thermo Fisher Scientific’s mycoplasma detection kit has been accepted by regulators for quality assurance, quality control and lot release.

The Applied Biosystems MycoSEQ Mycoplasma Detection Kit provides manufacturers of cell-culture-based therapeutics a faster method for detecting contamination, said the vendor.

The MycoSEQ assay can detect more than 90 mycoplasma species in less than five hours, offering drugmakers an alternative to “costly, time-consuming culture-based tests often done by externally contract labs, which can take up to 28 days,” ​the firm said.

The assay and method can be used for lot release by drugmakers of biotherapeutics, cell and gene therapies, vaccines, and other cell-culture-based medicines.

Head of pharma analytics Michael Brewer told us the technology was recently granted patents that cover its multiplexed PCR (polymerase chain reaction) primer approach and discriminatory positive/extraction control.

“These innovations to real-time PCR technology, which are unique to us, enable this rapid test for mycoplasma to meet the increasingly rigorous requirements of both regulatory authorities and manufacturers.”

Multiple pharmaceutical companies are using the assay, we were told.

“Several global manufacturers, including Vericel, across multiple therapeutic modalities have successfully validated the assay and achieved regulatory approval for lot release,” ​said Brewer. 

The technology is available to manufacturers worldwide.

Related news

Related products

show more

Difco TC Yeastolate UF in scale-up optimization

Difco TC Yeastolate UF in scale-up optimization

Content provided by Thermo Fisher Scientific Gibco Culture for Bioprocessing | 16-Oct-2023 | White Paper

Review the impact of—not only adding peptones as a supplement to your cell culture—but also the importance of concentration and timing as a feed strategy...

Related suppliers